DOCSLIB.ORG

Downloaded from Bioscientifica.Com at 10/02/2021 12:28:16PM Via Free Access 474 C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Downloaded from Bioscientifica.Com at 10/02/2021 12:28:16PM Via Free Access 474 C BIOLOGICAL ACTIVITY OF MEDROGESTONE A NEW ORALLY ACTIVE PROGESTIN C. REVESZ and C. I. CHAPPEL Ayerst Research Laboratories, Montreal, Canada [Received 12th February 1966) Summary. A new synthetic orally active progestational agent 'Medro- gestone' was investigated and its activity compared to progesterone and medroxyprogesterone acetate (map). Medrogestone fulfils the criteria of a pure gestagen, it has a spectrum of biological activity similar to that of progesterone but unlike progesterone, it is orally active. Medro- gestone is free of undesirable side effects in experimental animals. It is being investigated clinically as an oral progestin (Carter, Faucher & Greenblatt, 1964). INTRODUCTION The lack of oral effectiveness of progesterone inspired the search during recent years for progestational compounds which would be orally active. A number of such compounds have been synthesized, tested in animals and are now widely used in menstrual irregularities, habitual, threatened abortion, cycle regulation, treatment of infertility and/or in combination with oestrogens as contraceptives. However, many of these substances in addition to their pro¬ gestational activity produce certain side-effects such as androgenicity, mascu- linization of female foetuses and adrenal atrophy. The desirability of an orally active progestin which would be free from these objectionable properties led to the synthesis of a series of derivatives of 17-methylprogesterone (Deghenghi & Gaudry, 1961; Deghenghi, Revesz & Gaudry, 1963) and their testing as progestational agents. The biological activity of 6-methyl-6-dehydro-17- methylprogesterone, which appeared to be the most promising member of this series, forms the subject of this paper. It has the following structural formula: CH, * Generic name of 6-methyl-6-dehydro-17-methylprogesterone. Trade name in U.S.A. is Colprone, also known as -62022. t Present address: Bio-Research Laboratories, Pointe-Claire, Quebec, Canada. 473 Downloaded from Bioscientifica.com at 10/02/2021 12:28:16PM via free access 474 C. Revesz and C. I. Chappel METHODS Progestational activity McPhail's (1934) modification of the Clauberg test was employed using progesterone and medroxyprogesterone acetate (map) as reference compounds. Immature female rabbits were primed with a total dose of 15 ^g oestrone given over a period of 6 days. From the 7th to the 12th day of the experiment the test compound was given daily, subcutaneously (in 0-2 ml of sesame oil) or orally (in 2 ml of sesame oil). Twenty-four hours after the last dose was given the animals were killed and sections removed from the proximal, middle and distal portions of each uterine horn. Specimens were fixed in Bouin's solution, sectioned at 5 µ and stained with Harris's haematoxylin and eosin stain. The sections were evaluated according to McPhail's grading system. Duration of action ofprogestational activity The duration of effect of a single dose in the above test was determined by the method of Junkmann (1954). Progesterone, 17-hydroxyprogesterone caproate and map were used as reference compounds. Immature female rabbits were primed with oestrone as previously described. On the 7th day the compound was given in a single high dose subcutaneously. On the following days 0-025 ^g of oestrone was then given daily subcutaneously. Groups of five animals were killed 3, 7, 10, 13 and 17 days after receiving the test compound. Uterine sections were evaluated as above. Local progestational activity In this test McGinty, Anderson & McCullough's (1939) method was used with progesterone and map as reference compounds. Immature female rabbits were primed as described in the Clauberg test. On the 7th day of the experiment the rabbits were anaesthetized (Nembutal 30 mg/ kg i.v.) and the uteri were exposed. Ligatures were placed at each end of the upper 3 to 4 cm segment of each uterine horn. The upper ligatures were tied tightly and the lower ones left loose without disturbance of the blood supply to the tissue. The test compound (dissolved in 0-1 ml of sesame oil) was intro¬ duced into one of the isolated segments through an incision below the lower ligature. As the contents of the syringe were injected, the lower ligature was tightened. The same volume of sesame oil was injected into the other horn as a control. The rabbits were killed 72 hr later and sections of the isolated segment taken for histological examination. Deciduoma test The method of Elton & Edgren (1958) was used, with progesterone and map as reference compounds. Female hooded rats of the Long-Evans strain (140 to 160 g) were ovariecto- mized, allowed to recover for a week and then primed daily, for 4 days, with 5 µg of oestrone subcutaneously. The test compound was then given subcutane¬ ously daily for the following 9 days. On the 5th day of treatment with the test compound, the left horn of the uterus was exposed and 2-0 mg of histamine Downloaded from Bioscientifica.com at 10/02/2021 12:28:16PM via free access Biological activity of Medrogestone 475 dihydrochloride (in 0-05 ml distilled water) was injected into the lumen, while the right horn served as control. The animals were killed the day after the last subcutaneous injection. The uteri were dissected and the right and left horns weighed separately. Maintenance ofpregnancy test in rats The effect of Medrogestone in maintaining pregnancy was determined according to the method described by Madjerek, de Visser, van der Vies & Overbeek (1960), with progesterone and map as reference compounds. Effect of multiple doses. Groups of six female hooded rats of the Long-Evans strain were placed in cages which contained two mature males per cage. Vaginal smears were taken daily. The day spermatozoa were found in the smears was counted as Day 1 of the pregnancy and the animal was removed from the cage. On the 9th day of pregnancy the rats were ovariectomized and the number of implantations present in the uteri recorded. The test compound was given subcutaneously once daily, or orally twice daily, from the 9th to the 20th day of pregnancy. On the 21st day of pregnancy the uteri were removed through an abdominal incision and the living foetuses counted and weighed. The number of dead foetuses was also recorded. Effect of a single dose. The procedure and reference compounds were the same as when multiple doses were given except that after ovariectomy on the 9th day of pregnancy a single dose of the test compound was administered sub¬ cutaneously in 0-5 ml of sesame oil. The number of live foetuses found in each animal, divided by the number of implantations at the time of ovariectomy, multiplied by 100, was used as an index of the ability of a compound to maintain pregnancy. Ovulation inhibition in rats Ovulation was induced by the method of Wilson & Zarrow (1962). Nore¬ thynodrel, Enovid, Medrogestone and Medrogestone plus Premarin® were tested. Twenty-four-day-old female hooded rats were injected subcutaneously with 30 units of pmsg (pregnant mare serum gonadotrophin). Exactly 56 hr later, they were injected s.c. with 10 units of hcg (human chorionic gonadotrophin). The rats were killed and autopsied 24 hr after the hcg was given. The number of ova expelled from the oviduct was counted under the low power of a light microscope (Rowlands, 1942). The test compounds were given subcutaneously in 0-1 ml of sesame oil with the pmsg, 24 hr before the hcg and with the hcg. The ed50 for ovulation in¬ hibition was the daily dose of the test compound which reduced the number of ova by 50% as compared with the controls. Prevention ofpregnancy test Groups of five adult female hooded rats were injected with Medrogestone for 1 week before they were caged with sexually mature males. Treatment of the females was continued for 2 weeks after which the males were removed from the cages. Vaginal smears were taken during the experiment in order to Downloaded from Bioscientifica.com at 10/02/2021 12:28:16PM via free access 476 C. Revesz and C. I. Chappel detect spermatozoa. The females were checked for pregnancy 1 week after the males were removed. Gonadotrophin suppressant activity This activity was determined in parabiotic rats using the methods of Bunster & Meyer (1933) and Biddulph, Meyer & Grumbeck (1940). Medrogestone was tested alone and in combination with Premarin®. Oestrone was used as the standard. Pairs of 38- to 39-day-old hooded female litter-mates were united by surgical attachment of the lateral skin and abdominal muscles. One of the partners was spayed and given the test compound subcutaneously in sesame oil daily for 10 days. The animals were killed and autopsied on the morning of the 11th day of the experiment. Percentage ovarian inhibition was calculated according to Miyake (1961): 100 [V-C) [V-VJ ' where V average ovarian of the intact partner united with the — weights vehicle-injected spayed female; C = average ovarian weights of the intact partner united with the test compound injected spayed female; and Vt = average weights of the intact partner united with the vehicle- injected intact female. Androgenic and anabolic activity The Herschberger, Shipley & Meyer (1953) assay was used with testosterone propionate, progesterone and map as reference compounds. Twenty-one- to 23-day-old male rats (40 to 45 g) were castrated and given the test compound subcutaneously for 7 days, beginning on the day ofcastration. The animals were killed the day after the last injection and the weight of the levator ani, ventral prostate and seminal vesicles was recorded. Initial and final body weights were also determined. Anti-androgenie effects Some progestational agents have been reported to have strong anti-andro- genic effects. The compounds were assayed for this activity in castrated rats as described by Lerner, Bianchi & Borman (1960).
Load more

Recommended publications
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Off Enders
    How to select pharmacologic treatments to manage recidivism risk in sex off enders Consider patient factors when choosing off -label hormonal and nonhormonal agents ® Dowden Healthex offenders Media traditionally are managed by the criminal justice system, but psychiatrists are fre- Squently called on to assess and treat these indi- CopyrightFor personalviduals. use Part only of the reason is the overlap of paraphilias (disorders of sexual preference) and sexual offending. Many sexual offenders do not meet DSM criteria for paraphilias,1 however, and individuals with paraphil- ias do not necessarily commit offenses or come into contact with the legal system. As clinicians, we may need to assess and treat a wide range of sexual issues, from persons with paraphilias who are self-referred and have no legal involvement, to recurrent sexual offenders who are at a high risk of repeat offending. Successfully managing sex offenders includes psychological and pharmacologic interven- 2009 © CORBIS / TIM PANNELL 2009 © CORBIS / tions and possibly incarceration and post-incarceration Bradley D. Booth, MD surveillance. This article focuses on pharmacologic in- Assistant professor terventions for male sexual offenders. Department of psychiatry Director of education Integrated Forensics Program University of Ottawa Reducing sexual drive Ottawa, ON, Canada Sex offending likely is the result of a complex inter- play of environment and psychological and biologic factors. The biology of sexual function provides nu- merous targets for pharmacologic intervention, in- cluding:2 • endocrine factors, such as testosterone • neurotransmitters, such as serotonin. The use of pharmacologic treatments for sex of- fenders is off-label, and evidence is limited. In general, Current Psychiatry 60 October 2009 pharmacologic treatments are geared toward reducing For mass reproduction, content licensing and permissions contact Dowden Health Media.
    [Show full text]
  • Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom
    No. LCMSMS-065E Liquid Chromatography Mass Spectrometry Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole No. LCMSMS-65E Mass Spectrometry This application news presents a method for the determination of 17 hormone residues in milk using Shimadzu Ultra-High-Performance Liquid Chromatograph (UHPLC) LC-30A and Triple Quadrupole Mass Spectrometer LCMS- 8040. After sample pretreatment, the compounds in the milk matrix were separated using UPLC LC-30A and analyzed via Triple Quadrupole Mass Spectrometer LCMS-8040. All 17 hormones displayed good linearity within their respective concentration range, with correlation coefficient in the range of 0.9974 and 0.9999. The RSD% of retention time and peak area of 17 hormones at the low-, mid- and high- concentrations were in the range of 0.0102-0.161% and 0.563-6.55% respectively, indicating good instrument precision. Method validation was conducted and the matrix spike recovery of milk ranged between 61.00-110.9%. The limit of quantitation was 0.14-0.975 g/kg, and it meets the requirement for detection of hormones in milk. Keywords: Hormones; Milk; Solid phase extraction; Ultra performance liquid chromatograph; Triple quadrupole mass spectrometry ■ Introduction Since 2008’s melamine-tainted milk scandal, the With reference to China’s national standard GB/T adulteration of milk powder has become a major 21981-2008 "Hormone Multi-Residue Detection food safety concern. In recent years, another case of Method for Animal-derived Food - LC-MS Method", dairy product safety is suspected to cause "infant a method utilizing solid phase extraction, ultra- sexual precocity" (also known as precocious puberty) performance liquid chromatography and triple and has become another major issue challenging the quadrupole mass spectrometry was developed for dairy industry in China.
    [Show full text]
  • Referral Support Service Gynaecology
    Referral Support Service Gynaecology GY11 Heavy Menstrual Bleeding (Menorrhagia and Polymenorrhagia) Definitions Menorrhagia: Excessive menstrual blood loss which interferes with the woman’s physical, emotional, social and material quality of life and which can occur alone or in combination with other symptoms. Polymenorrhagia: Frequent heavy bleeding, with shortening of menstrual cycle (eg < K- 5/21) for more than 3 cycles. Most cases are due to Dysfunctional uterine bleeding (DUB), however, this is a diagnosis of exclusion. Exclude Red Flag Symptoms Postmenopausal Bleeding (PMB) i.e. bleeding >12 months after last period over age 55 Persistent Intermenstrual bleeding (IMB): if >45 or other risk factors for endometrial cancer (eg obesity, PCOS unopposed oestrogen, tamoxifen) Treatment failure in women aged 45 years or over Significant anaemia- Hb< 8- consider admission for transfusion/ urgent referral Suspicious USS features General Points History: Sudden change in bleeding pattern? Recent childbirth? Recent change in contraception? Family history/ onset of HMB from puberty- consider von Willebrand Disease. Examination: Consider infection (especially if under 25 or change in partner) Abdominal examination/ Pelvic examination (is there pain, is there an enlarged uterus?) Investigations: Bloods: FBC, TFTs.(check for vWF if onset of HBM from puberty) Consider USS if enlarged uterus or new change in bleeding pattern. Refer for hysteroscopy if any suspected polyps or thickened endometrium on USS. How to Reduce Sudden/New onset
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    PHARMACEUTICALS volume 100 A A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 14-21 October 2008 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007).
    [Show full text]
  • Effect of Tibolone on Bone Mineral Density in Postmenopausal Women: Systematic Review and Meta-Analysis
    biology Review Effect of Tibolone on Bone Mineral Density in Postmenopausal Women: Systematic Review and Meta-Analysis Lizett Castrejón-Delgado 1, Osvaldo D. Castelán-Martínez 2 , Patricia Clark 3, Juan Garduño-Espinosa 4, Víctor Manuel Mendoza-Núñez 1 and Martha A. Sánchez-Rodríguez 1,* 1 Research Unit on Gerontology, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Mexico City 09230, Mexico; [email protected] (L.C.-D.); [email protected] (V.M.M.-N.) 2 Clinical Pharmacology Laboratory, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Mexico City 09230, Mexico; [email protected] 3 Clinical Epidemiology Research Unit, Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico; [email protected] 4 Research Department, Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico; [email protected] * Correspondence: [email protected]; Tel.: +52-55-5623-0700 (ext. 83210) Simple Summary: Low bone mineral density (osteoporosis) is associated with vertebral and non- vertebral fractures in postmenopausal women. Tibolone is a low-risk hormone replacement therapy alternative to estrogen therapy, effective in the treatment of menopausal symptoms and prevention of bone loss, but the evidence is controversial. This systematic review with meta-analysis summarizes Citation: Castrejón-Delgado, L.; the clinical trials of the tibolone effect on percentage change of bone mineral density in the lumbar Castelán-Martínez, O.D.; Clark, P.; spine, femoral neck, and total hip in postmenopausal women. The results show that tibolone 2.5 mg Garduño-Espinosa, J.; dose increases the percent change in bone mineral density compared with non-active controls at Mendoza-Núñez, V.M.; 24 months in lumbar spine and femoral neck, regardless of the scanner used to evaluate the bone Sánchez-Rodríguez, M.A.
    [Show full text]
  • The Realization of New Medical Alternatives to Surgery for Endometriosis
    Paradigm Shift: The Realization of New Medical Alternatives to Surgery for Endometriosis Edward M. Lichten, MD* ©2016, Edward M. Lichten, MD Journal Compilation ©2016, AARM DOI 10.14200/jrm.2016.5.0099 ABSTRACT Endometriosis is one of the most destructive benign diseases of women. It is established as developing and being present in upward of 70% of adolescents who do not experience relief of menstrual pain with use of oral contraceptives and anti- inflammatory drugs. It occurs in 8%–10% of women in the United States and is most prevalent in developed countries. Symptoms of endometriosis include disabling pain, hemorrhagic uterine bleeding, and infertility. Women with disease can expect a 12% hysterectomy rate. While present medical therapy may offer relief of many symptoms, there have been no major new directions in pharmacologic therapy since leuprolide acetate was made available in 1977. Danazol remains the only alternative to GnRH agonists with proven efficacy and reasonable side effects, according to Cochrane Reviews, yet, it is underused, and GnRH agonists are favored even when Danazol in combination seems more effective. A previously published case report on use of the combination of nandrolone and stanozolol to treat a young woman scheduled for hemicolectomy is discussed as an alternative to surgery along with the limits of standard therapy. This review will focus on recent research and theories seeking to establish causation for disease and offer treatment recommendations. Keywords: Endometriosis; Environmental toxins; Xenoestrogens;
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • PCR Analysis of Androgen-Regulated Genes in Human Lncap Prostate Cancer Cells
    Oncogene (2009) 28, 2051–2063 & 2009 Macmillan Publishers Limited All rights reserved 0950-9232/09 $32.00 www.nature.com/onc ONCOGENOMICS Microarray coupled to quantitative RT–PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells S Ngan, EA Stronach, A Photiou, J Waxman, S Ali and L Buluwela Department of Oncology, Imperial College London, London, UK The androgen receptor (AR) mediates the growth- 2006). The importance of AR in male development is stimulatory effects of androgens in prostate cancer cells. shown by the androgen insensitivity syndromes char- Identification of androgen-regulated genes in prostate acterized by mutations in the AR gene (Gottlieb et al., cancer cells is therefore of considerable importance for 2004). The prostate is a prototypical androgen-depen- defining the mechanisms of prostate-cancer development dent organ (Cunha et al., 1987; Davies and Eaton, 1991) and progression. Although several studies have used and prostate cancer, which has become the most microarrays to identify AR-regulated genes in prostate commonly diagnosed cancer in males in the western cancer cell lines and in prostate tumours, we present here world and is the second leading cause of male cancer the results of gene expression microarray profiling of the death, is androgen-dependent for its growth (Carter and androgen-responsive LNCaP prostate-cancer cell line Coffey, 1990; McConnell, 1991). Therefore, treatment is treated withR1881 for theidentification of androgen- directed at inhibiting prostate cancer growth by regulated genes. We show that the expression of 319 genes suppressing the action of the endogenous androgen or is stimulated by 24 hafter R1881 addition, witha similar its production.
    [Show full text]
  • DRUG NAME: Medroxyprogesterone
    Medroxyprogesterone DRUG NAME: Medroxyprogesterone SYNONYM(S): MPA,1 acetoxymethylprogesterone, methylacetoxyprogesterone,2 17-hydroxy-6-alpha- methylprogesterone3 COMMON TRADE NAME(S): PROVERA® CLASSIFICATION: endocrine hormone Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Medroxyprogesterone (MPA) is a progestin used in endometrial and breast cancers.4 In endometrial cancer, MPA inhibits secretion of luteinizing hormone and follicle-stimulating hormone from the pituitary gland. In breast cancer, MPA blocks the effect of adrenocorticotropic hormone (ACTH) from the pituitary gland.5,6 Peripheral mechanisms of MPA include binding to progesterone, glucocorticoid, and androgen receptors6-8 resulting in decreased number of estrogen receptors and decreased estrogen and progesterone levels peripherally in target tissues.3,6 The growth 9 inhibitory effects of progestins are not cell cycle phase-specific, but may be maximal in the G1 phase. PHARMACOKINETICS: Interpatient Variability high doses are required to generate low-drug plasma levels and to overcome interpatient variation in absorption and metabolism10,11 Oral Absorption rapid; peak concentration in 2-4 h; up to 10% of dose absorbed11; bioavailability increased with food; steady state in 4-10 days10,11 Distribution widely distributed centrally and peripherally2 cross blood brain barrier? yes volume of distribution10 25-300 L plasma protein binding 90% Metabolism primarily hepatic via CYP 3A4; more than 10 metabolites of unknown activity3 active metabolite(s) no information found inactive metabolite(s) no information found Excretion primarily via feces urine 44% (as metabolites); primary metabolite: 6α-methyl- 6β,17α,21-trihydroxy-4-pregnene-3,20-dione-17-acetate (8%) feces10 45-80% (as metabolites) terminal half life4,7,10,11 12-72 h clearance10-12 27-70 L/h Elderly no differences Adapted from standard reference4 unless specified otherwise.
    [Show full text]
  • The Hormone Replacement Therapy Drug Tibolone Acts Very Similar To
    405 The hormone replacement therapy drug tibolone acts very similar to medroxyprogesterone acetate in an estrogen- and progesterone-responsive endometrial cancer cell line P Hanifi-Moghaddam, B Sijmons, M C Ott4, W F J van IJcken2, D Nowzari, E C M Kuhne, P van der Spek3, H J Kloosterboer5, C W Burger1 and L J Blok Departments of Reproduction and Development, 1Obstetrics and Gynecology, 2Center for Biomics, 3Bioinformatics, Erasmus University Medical Center, 3000 DR Rotterdam, The Netherlands, 4OmniViz, Inc., Maynard, Massachusetts, USA and 5Research and Development Laboratories, N V Organon, 5340 BH Oss, The Netherlands (Requests for offprints should be addressed to P Hanifi-Moghaddam; Email: p.hanifi[email protected]) Abstract Tibolone, a steroidogenic compound with both estrogenic and progestagenic properties, is used as an alternative for estrogen or estrogen plus progesterone hormone therapy for the treatment of symptoms associated with menopause and osteoporosis. We have evaluated whether the effect of tibolone on a human endometrial cell line is similar to, or comparable with, the effect of estradiol (E2), medroxyprogesterone acetate (MPA) or E2CMPA treatment. Using stable transfection techniques, the estrogen receptor (ER) expressing human endometrial cancer cell line, ECC1, was altered to also express both progesterone receptors (PRs). These cells were then used to assess growth regulation and expression profiling (Affymetrix U133plus2) under the influence of E2 (1 nM), MPA (1 nM), E2CMPA or tibolone (100 nM). Growth assessment and comparison of profiles indicate that tibolone behaves predominantly like MPA. Furthermore, regulation of prereplication complex genes, such as the minichromosome maintenance genes, could be involved in the observed strong inhibition of growth by tibolone as well as MPA.
    [Show full text]